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Non-invasive prediction of aluminum bone disease in hemo- and
peritoneal dialysis patients. Between October 1987 and October of 1989,
we conducted a prospective study to evaluate non-invasive test strate-
gies for predicting aluminum bone disease (ABD) in a group of largely
unselected dialysis patients based on their deferoxamine (DFO) test
alone, or the combined results of their DFO test and intact 1-84
parathyroid hormone (PTH) levels. These test parameters were evalu-
ated against the pathological diagnosis of ABD based on bone biopsy
("gold standard"). A total of 445 patients in three dialysis centers in
Toronto were serially followed for their clinical, laboratory and risk
parameters for renal osteodystrophy during the study, and 259 (142 PD
and 117 HD) patients underwent a series of investigations which
included the DFO test, measurement of intact 1-84 PTH levels, and an
iliac crest bone biopsy. Serum aluminum ([Al]) level  3700 nM (or 100
sg/liter) had a positive predictive value (PPV) of 75% for ABD in our
PD and 88% in our HD patients, but its sensitivity was low (10 and
37%). Delta [Al] (that is, incremental rise of serum [Al] from baseline
post-DFO) was useful in predicting ABD in our PD but not HD patients.
Test combination based on delta [Al] 5550 ni (or 150 pg/liter) and
PTH level <20 pM (or 200 pg/mI) yielded the best PPV  95% for ABD
in both PD and HD patients. This test cut-off would remain highly
predictive of ABD even if the prevalence of ABD decreases to as low as
5% for the PD patients and 10% for the HD patients. However, for
patients who have discontinued their aluminum gels for 6 months
these test strategies would not be useful due to a very high frequency of
false-negative cases (or low sensitivity). Thus, the main utility of these
non-invasive strategies will be in those patients who continue to require
treatment of aluminum gels for their phosphate control.
Aluminum intoxication is an important complication in pa-
tients on chronic maintenance dialysis, and is associated with
serious morbidity and mortality [1—3]. Aluminum bone disease
(ABD) is the most common finding in this iatrogenic syndrome
and significantly limits the quality of life of affected patients [1,
21.
Since ABD is associated with a large tissue burden of
aluminum and low levels of parathyroid hormone (PTH), the
deferoxamine (DFO) test (see section on Special Investigations
below) and PTH levels have been thought to be useful param-
eters in predicting this bone lesion [2—6]. Indeed, previous
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studies have examined the role of these tests in predicting ABD
in dialysis patients with musculoskeletal symptoms [5—7]. How-
ever, no study thus far has defined the usefulness of these tests
in unselected patients. Furthermore, the validity of these tests
will need to be redefined in the context of a declining incidence
of ABD due to the restricted use of aluminum-containing
phosphate binders in current clinical practice [3]. We have
examined these issues in the present study.
Methods
The Renal Osteodystrophy Study was initiated in October of
1987 as a tn-center project involving the Toronto General,
Wellesley and Sunnybrook Hospitals. It was a prospective,
cross sectional study of renal bone diseases in a large popula-
tion of dialysis patients in Toronto. The study was terminated in
October of 1989.
Study design and data collection
Since 1981, the Toronto Renal Failure Registry has prospec-
tively documented certain co-morbid events in all patients at
their entry into the End-stage Renal Failure (dialysis and
transplantation) Program and annually thereafter in a comput-
erized data registry. In the Renal Osteodystrophy Study, we
utilized the database from the Toronto Renal Failure Registry
on renal bone disease risk factors and events for the initial
assessment of bone disease in all the dialysis patients in the
study centers. All events entered into our initial assessment
database were confirmed from the patients' medical records and
recorded in a standardized form by the research assistant. All
patients in the study were managed by their own nephrologists
according to a standardized protocol. They were then prospec-
tively followed and serially reassessed every three to four
months for their clinical, routine laboratory and risk parameters
for bone disease by the research assistant using a standardized
form.
Clinical parameters assessed included: musculoskeletal find-
ings of proximal myopathy (tested at the time of bone biopsy),
unexplained bone pain or pathological fracture(s); unexplained
neurological findings of ataxia, dyspraxia, seizure or dementia;
laboratory parameters assessed included serum total protein,
albumin, calcium, phosphorus, alkaline phosphatase, hemoglo-
bin, MCV and serum aluminum. Risk factors for bone disease
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assessed included: patient age, sex, dialysis duration, dialysis
modality, diabetes mellitus, phosphate binder type, cumulative
dose of aluminum hydroxide gel ingested since dialysis, previ-
ous parathyroidectomy, bilateral nephrectomy and failed renal
transplant. Hypercalcemia was defined as repeated serum cal-
cium greater than 2.7 msi (10.8 mg/dl), and unexplained micro-
cytic anemia was defined as hemoglobin less than 100 g/liter
with MCV <80 fi excluding iron-deficiency or thalassemia. All
data collected were prospectively entered into a computerized
database specifically designed for the study.
Special investigations
Intact 1-84 parathyroid hormone (1-84 i-PTH). Plasma sam-
ples were assayed using an immunoradiometric assay (IRMA)
(by Dr. G. Segre, MGH, Boston, USA) with specificity for
intact PTH and does not detect carboxyl-terminal fragments
(normal range: 1 to 5.5 p or 10 to 55 pg/mI) [8]. All samples
were collected prior to heparinization in hemodialysis patients.
Deferoxamine (DFO) test. This was performed using a stan-
dard DFO dose of 40 mg/kg i.v. in hemodialysis and i.p. in
peritoneal dialysis patients. Pre- and post-DFO (drawn 36 to 48
hr post-DFO in hemodialysis and 18 to 24 hr post-DFO in
peritoneal dialysis patients) serum aluminum levels were col-
lected using trace mineral tubes [9]. All aluminum-containing
medication, including aluminum gels and sucralfate, were dis-
continued 48 hours prior to the sampling of the pre-DFO serum
aluminum level. They were restarted only after the post-DFO
serum aluminum level was sampled. All serum aluminum levels
were measured by Dr. S. Krishnan (Medical Physics Labora-
tory, Toronto General Hospital, Canada) using graphite furnace
atomic absorption spectrophotometry with a normal reference
range < 560 flM (100 nM = 2.7 pg/liter) [9]. Delta aluminum
(Delta [Al]) was defined as the incremental rise of serum
aluminum level after DFO as compared to baseline (that is,
post-DFO minus pre-DFO aluminum level) [6, 10].
Bone biopsy. A standard technique previously reported was
used in our study [10]. Briefly, double-tetracycline labelling
with two short courses of two different tetracyclines (tetracy-
cline and demeclocycline), separated by an interval of 17 days,
were given to all study patients prior to the bone biopsy. Under
local anesthesia with i.v. sedation (with diazepam and meperi-
dine), an anterior iliac crest bone biopsy was then performed
using a modified Bordier needle 4 to 10 days after the last dose
of demeclocycline. All biopsy specimens were fixed in 10%
neutral phosphate-buffered formalin for 24 hours and then
transferred to 70% ethanol. Undecalcified sections of trabecular
bone were stained by the Goidner method [11, 121, by aurin-
tricarboxylic acid for detection of aluminum [12], and by
prussian blue for iron staining.
Class ification of renal bone lesions
The following histologic classification was used in this study
and had been detailed previously [11]: (i) aplastic lesion (bone
formation rate (BFR) < 108 m2/mm2/day; osteoid area (OA) <
15%; and fibrosis < 0.5%); (ii) osteomalacia (BFR < 108
zm2/mm2/day; OA  15%; and fibrosis <0.5%); (iii) mild lesion
(BFR  108 m2/mm2/day; OA < 15%; and fibrosis < 0.5%);
(iv) osteitis fibrosa (OF) (BFR  108 prn2/mm2/day; OA < 15%;
and fibrosis 5%); (V) mixed lesion (Mx) (BFR  108
sm2/mm2/day; OA  15%; and fibrosis  0.5%).
Aluminum bone disease (ABD) was defined in our study as all
cases of aplastic lesion or osteomalacia with stainable bone
surface aluminum (SBSA)  25% [13]. In addition, mild and
mixed lesions with SBSA  25% and "normal" BFR (108 <
BFR  250 m2/mm2/day) were defined as "transitional"
lesions related to aluminum intoxication and included as ABD.
For the purpose of our study, osteitis fibrosa and mixed lesion
(with surface aluminum < 25%) were combined as a single
diagnostic group (OF/Mx). In addition, all cases of aplastic
lesions with SBSA <25% were included as the aplastic (APL)
group. Lastly, all cases of mild lesion and osteomalacia with
SBSA < 25%, as well as indeterminate cases that did not fit into
any of the above groupings were included in the miscellaneous
(MISC) group.
Study patients
Four hundred and forty-five of all the "current" as well as
new patients entering either the hemo- or peritoneal dialysis
program in the study centers (Toronto General, Wellesley and
Sunnybrook Hospitals) between 1/10/87 and 30/6/88 were as-
sessed serially during the study period. All patients who were
on dialysis for at least one year and had no concomitant acute
medical illness were entered into a central pool which was
continuously updated during the study. Two hundred and
forty-eight patients were randomly selected from this pooi by
their registry number by the research assistant, and twenty
more were referred because of their clinical findings of bone
disease. At the termination of our study, 268 patients (60% of
total population) underwent the above special investigations.
The bone biopsy and/or deferoxamine test specimens were lost
in 4 of the 268 patients; and in 5 other patients, their biopsy
specimens were inadequate for a pathologic diagnosis. Thus,
the final study population consisted of 259 patients who were
serially followed and had adequate data on all the special
investigations including the bone biopsy (the "gold standard").
Of the non-biopsy patients, two thirds of them died or were
transplanted during the study period, and thus, were not
available for the special investigations. The clinical and risk
parameters of the non-biopsy patients for renal bone disease
(including age, dialysis modality and duration, phosphate bind-
ers, diabetes mellitus, and previous renal transplant and para-
thyroidectomy) were not significantly different from the bi-
opsied patients. Overall, only 20 of a total of 288 patients who
were asked to undergo the special investigations refused.
All the study patients gave informed consent after a full
explanation of the details, procedures, and potential risks of the
study. The research protocol and consent form were approved
by the institutional review board of the University of Toronto.
Evaluation of test strategies in predicting aluminum bone
disease
We evaluated three different test strategies for predicting
ABD for our PD and HD patients separately: (i) random serum
aluminum level (s-[A1]); (ii) delta [Al]; and (iii) the combined
test results of delta [Al] and PTH level. For each of the above
parameters, we arbitrarily selected several test cut-offs for
predicting ABD and defined their test characteristics as follows:
positive (PPV) and negative (NPV) predictive value; sensitivity
(SEN); specificity (SPEC); and likelihood ratio for a positive
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Data expressed as mean (± SD) or %.
a 1 mM is equivalent to 4 mg/dl
b m is equivalent to 3 mg/dI
C 10 M is equivalent to 100 pg/mI
d 100 nM is equivalent to 2.7 gIliter
test (LR(+)) (see Appendix A) 114, 15]. For s-IA!] and delta [A!],
the cut-offs tested included:  1850, and 7400
flM (3700 flM = 100 pjg/liter). For the combined test strategies,
12 combinations were tested: delta [Al] 1850,
or 7400 flM and PTH < 10, 20 or 30 pM.
Statistical methods
All descriptive data were expressed as means SD, or
percent. Statistical testing for hypothesis generation only was
performed on these parameters using unpaired t-test for contin-
uous variables, and chi-square test (or Fisher's exact test if
appropriate) for proportions. All P-values reported are two-
tailed.
To evaluate the cut-offs of the above test parameters for
predicting ABD, we generated their PPV, NPV, SEN, SPEC,
and LR(+) using a SAS computer program [16]. To examine the
effect of declining incidence of ABD on the predictive perfor-
mances of the above test parameters, we applied the Bayes'
theorem to calculate the hypothetical post-test probabilities of
ABD based on its pre-test probabilities (that is, prevalence of
ABD) and the LR(+) of each test condition (see Appendix B)
[151.
Results
Patient characteristics
Of the 259 study patients, 45% were on hemodialysis, 45%
were on continuous ambulatory peritoneal dialysis (CAPD),
and 10% were on intermittent peritoneal dialysis (IPD). Table 1
shows our patient characteristics by their dialysis modality [that
is, peritoneal dialysis (PD) and hemodialysis (HD)1. In general,
our PD patients were older, on dialysis for a shorter duration,
and were more commonly diabetic than our HD patients. In
addition, more PD patients were on calcium carbonate as their
sole phosphate binder in contrast to our HD patients who had a
much larger cumulative exposure to aluminum gels. Laboratory
investigations at the time of bone biopsy revealed that our HD
0
ABD OF/Mx APL MISC
Fig. 1. Prevalences of different bone disorders by dialysis modality
[peritoneal (U) versus hemodialysis (c)]. Aluminum bone disease
(AED) and osteitis fibrosa/mixed lesion (OF/Mx) were more prevalent
in our HD patients (P = 0.066 and < 0.0001, respectively), whereas
aplastic lesion (with stainable surface aluminum <25%; APL) was more
prevalent in our PD patients. Expressed as percent of PD (N = 142) and
HD (N = 117) patients.
patients had more severe hyperparathyroidism, as evidenced by
their higher levels of PTH and serum alkaline phosphatase, and
greater aluminum exposure as evidenced by their higher serum
[Al] and delta [Al] when compared to our PD patients. Not
surprisingly, therefore, the prevalences of bone lesions in these
two groups of patients were also different as shown in Figure 1.
Our HD patients appeared to have a higher prevalence of ABD
(33% vs. 22%; P = 0.066) and OF/Mx lesions (44% vs. 13%; P
< 0.0001) when compared to our PD patients. In contrast,
almost half of our PD patients had the APL lesion (with less
than 25% surface aluminum staining). The MISC group as
defined above consisted of 30 cases of the mild lesion, one case
of osteomalacia, and two indeterminate cases. Clinically, pa-
tients in the ABD or OFIMx groups were most likely to have
findings of symptomatic metabolic bone disease as shown in
Table 2, Proximal myopathy in the shoulder and hip girdles
although common in these patients were generally mild. The
majority of pathologic fractures in our study patients were
localized to the ribs, vertebral bodies and hips.
Serum aluminum levels and prediction of aluminum bone
disease
The PPV for ABD based on random serum aluminum (s-[Al])
levels  3700 nM (100 sg/1iter) was 75% for our PD and 88% for
our HD patients; however, their SEN was only 10 and 37%,
respectively. Serum [Al] < 1850 nM (50 pg/liter) did not rule out
ABD as the NPV was 86% for our PD and 82% for our HD
Table 1. Patient demographics and laboratory
of bone biopsy
parameters at the time
CAPD/IPD Hemodialysis P valueN = 142 N = 117 (2-tailed)
Age at biopsy years 60 12 52 15 <0.0005
Dialysis duration years 3.2 3.6 5.3 5.4 <0.0005
Cumulative Al (OH)3 1.9 3.6 4.3 5.4 <0.0005
dose since dialysis kg
On CaCO3 only % 38 17 <0.0005
Diabetes mellitus % 30 19 <0.05
Failed renal allograft % 10 21 <0.02
Parathyroidectomy % 4 6 NS
s-[Ca] (mM)a 2.4 0.24 2.4 0.22 NS
s-[P04J (mM)b 1.8 0.48 2.1 0.76 <0.0005
ALP lU/liter 90 60 120 108 <0.005
1-84 PTH (pM)" 13 14 30 37 <0.0005
Serum [Al] (nMY 1080 1430 2060 1840 <0.0005
Delta serum [Al] post- 1740 1450 3750 2640 <0.0005
DFO flM
60-
40 -
20 -
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Table 2. Clinical and laboratory findings in patients with different
bone disorders
ABD OF/Mx APL MISC(N 69) (N = 69) (N = 88) (N = 33)
Proximal myopathy 64 48 9 9
Pathologic fracture(s) 15 9 1 0
Unexplained bone pain 47 38 2 6
Unexplained CNS findingsa
Microcytic anemiab
7
22
0
3
0
2
0
3
Hypercalcemia 59 36 21 15
Data expressed as percent of (N) for each bone disorder group:
aluminum bone disease (ABD); osteitis fibrosa or mixed lesion (OF!
Mx); aplastic lesion (with <25% of stainable surface aluminum) (APL);
and miscellaneous lesions (MISC).
a Encephalopathy/dementia without obvious explanationb MCV < 80 fi; excluding iron deficiency or thalassemia
patients. Twenty-nine out of 69 patients with ABD had s-[AlI
levels < 1850 flM.
Deferoxamine test and prediction of aluminum bone disease
Table 3 shows the performance of the DFO test in predicting
ABD in our PD and HD patients using different delta [Al]
cut-offs. Delta [Al]  7400 nM (200 jsg/liter) as a test cut-off was
not included since its PPV and SEN were not different from the
cut-off based on delta [Al] > 5550 nM (150 pg/liter). Delta [Al]
was useful in our PD patients in predicting ABD when the test
cut-off was either 3700 or flM since both their LR(+)
and PPV were high. Thus, patients who satisfy the cut-off of
delta [Al]  3700 n would have a PPV for ABD of 73% up
from a baseline probability of 22% and a SEN of 52%; while
patients with delta [Al]  5550 n would have a PPV for ABD
of 86% and a SEN of 39%.
However, using the same delta [Al] cut-offs in our HD
patients would only increase the PPV from 33% (pre-test) to 54
to 59% (post-test) and therefore, would be marginally useful.
The PPV based on a random serum [Al] level  3700 n would
perform better, although its SEN was lower.
Patients with a delta [Al] < 1850 flM (50 sgfliter), on the other
hand, had a low probability for ABD of about 10% (that is, NPV
of about 90% for delta [Al]  1850 nM) for both PD and HD
patients.
Limitations of the deferoxamine test as a diagnostic test
Figure 2 shows the explanation for the suboptimal perfor-
mances of the delta [Al] cut-offs for predicting ABD in our HD
patients. Among the non-ABD groups in both PD and HD
patients, post-DFO levels of s-[Al] were high in the OFIMx
patients (and also the MISC group in HD patients), and this
accounted for most of the false positive results based on the
DFO test. However, more than 50% (59 of 117) of our HD
patients belonged to the OF/Mx and MISC groups whereas only
13% (18 of 142) of our PD patients had the OF/Mx lesion. Thus,
the problem of false positive results was most accentuated in
our HD patients.
We also examined the aluminum gel ingestion patterns in our
patients in relation to their DFO test to determine if it could
provide an explanation for the suboptimal sensitivities of the
delta [Al] cut-offs (Fig. 3). Fourteen of 31(45%) PD patients and
12 of 38 (32%) HD patients with ABD had discontinued their
Table 3. Selected test characteristicsa of delta [Al] cut-offs for
predicting aluminum bone disease (ABD) in peritoneal (CAPD/IPD)
and hemodialysis patients
Delta [Al]"
flM LR(+) PPV SEN NPV SPEC
Peritoneal dialysis patients (N = 142)
Prevalence (pre-test probability) of ABD = 22%
1850 4.61 0.56 0.65 0.90 0.86
(N = 80)C
3700 9.55 0.73 0.52 0.88 0.94(N = 54)
5550 21.5 0.86 0.39 0.85 0.98
(N = 34)
Hemodialysis patients (N 117)
Prevalence (pre-test probability) of ABD = 33%
l850 1.54 0.43 0.90 0.89 0.42
(N = 36)
3700 2.41 0.54 0.76 0.86 0.68
(N = 22)
5550 2.94 0.59 0.53 0.78 0.82
(N = 14)
a LR(+) (likelihood ratio); PPV (positive predictive value); SEN
(sensitivity); NPV (negative predictive value); SPEC (specificity). See
appendices (A) and (B) for definitions.
"3700 nM = 100 g!1iter.
C N denotes the number of patients who have satisfied the specific
test cut-off
aluminum gel intake for at lest six months prior to their DFO
test (mean SD = 9 3 months). The false negative tests in
these 26 patients were far more common than in those patients
who remained on the aluminum gel at the time of their DFO
testing. For example, using delta [Al]  3700 nM as a test
cut-off, 86% (12 of 14) of our PD patients who had discontinued
their aluminum gel had a false-negative test result, as compared
to 18% (3 of 17) of PD patients who remained on aluminum gels
at the time of the DFO test (P < 0.0005; Fig. 3A). Similarly,
significant differences (P < 0.005) in false negative rates can be
found in HD patients using the same test cut-off (Fig. 3A), or in
both groups of patients using delta [Al]  5550 n as a test
cut-off (Fig. 3B). Thus, there was an unusually high false
negative rate (or very low SEN) when the DFO test was
performed in our PD or HD patients who had discontinued their
aluminum gels for  six months. However, there was no
difference between the mean values (±sD) of the stainable bone
surface aluminum (49 15% vs. 46 16%; P = NS), and the
bone formation rate (70 67 vs. 82 120 jsm2/mm2/day; P =
NS) in the above patients with ABD who had discontinued
versus those who remained on their aluminum gel.
Combined test strategy in predicting aluminum bone disease
Since ABD is generally associated with high delta [Al] and
low PTH levels [2—5, 13], we examined a combined test strategy
using the two above parameters. We defined the performances
of the following 12 arbitrary test combinations separately for
our PD and HD patients: delta [Al]  1850, or
7400 n and PTH < 10, 20 or 30 p. We selected the best test
combinations based on their LR(+), PPV and SEN. Table 4
shows the two best combinations: delta [Al]  3700 nM and
PTH < 20 p, and delta [Al]  5550 flM and PTH < 20 p, both
ABD OF/Mx APL MISC ABD OF/Mx APL MISC
(N = 31) (N = 18) (N = 68) (N 25) (N = 38) (N = 51) (N = 20) (N = 8)
Fig. 2. Serum aluminum (s-fAll) levels pre-DFO (R) and post-DFO () in peritoneal (PD) and hemodialysis (HD) patients according to their bone
disorders (expressed as mean SD). Patients with OF/Mx lesions generally had higher delta [Al] than other non-ABD groups, contributing to most
of the false-positive cases of the DFO test. Since many more HD than PD patients had the OF/Mx lesions, there were more false-positive cases
in our HD patients accounting for their low positive predictive values for ABD based on delta [Al] testing.
of which performed with very high LR(+) and PPV. Although
the LR(+) and PPV of delta LA1]  3700 nM and PTH <20 M
were slightly lower when compared to delta [All  5550 flM and
PTH <20 p, this combination had higher SEN.
Effects of decreasing prevalence of aluminum bone disease
on its prediction
With restricted use of aluminum-containing phosphate bind-
ers, the incidence and prevalence of ABD would be expected to
fall with time. Thus, we examined the effect of decreasing
prevalence of ABD on the predictive performances of delta
[Al], and the test combinations based on delta [AU and PTH
levels by using the Bayes' theorem (see Appendix B) [14, 151.
Figure 4 shows the relationship between the prevalences (pre-
test probabilities) and post-test probabilities of ABD based on
the test conditions of delta [Al]  3700 and flM in both
PD and HD patients. A range of hypothetical prevalences of
ABD was used, and the actual prevalence of ABD in our patient
groups was also shown (denoted as *) [16].
For our PD patients, delta [Al] 3700 flM is useful in placing
patients in the "moderate to high-risk" category with post-test
probabilities of 51 to 70% when the prevalence of ABD ranges
from 10 to 20% (Fig. 4A). Using delta [Al]  5550 n in the
same patient group, the post-test probabilities would be even
higher at 70 to 84% for the same range of prevalences (Fig. 4B).
Thus, these cut-offs would still be useful for a prevalence of
ABD decreasing to about 10%. However, the same delta [Al]
cut-offs would add marginally to the PPV in our HD patients, as
previously discussed.
The effects of a decreasing prevalence of ABD on the
predictive performances of the test combinations of delta [Al]
3700 aM and PTH < 20 PM, and delta [All  5550 flM and PTH
<20 M are shown in Figure 5. Their predictive performances
are very similar in both PD and HD patients across a wide range
of prevalences of ABD. This is due to a significant improvement
in the prediction of ABD in our HD patients using these
strategies. For our PD patients who satisfy the test combination
of delta [Al] 5550 nM and PTH < 20 p, the post-test
probability can be raised to almost diagnostic certainty. Pa-
tients who satisfy the test combination of delta [Al] 3700 nM
and PTH < 20 PM can thus be categorized as "moderate to
high-risk" even with a prevalence of ABD as low as 10%, while
those who satisfy delta [All  5550 flM and PTH <20 PM can be
categorized as very "high-risk" even with a prevalence of ABD
as low as 5% for the PD patients and 10% for the HD patients.
Discussion
Aluminum intoxication is a serious complication in patients
on chronic maintenance dialysis with significant morbidity and
mortality. Aluminum bone disease is an invariable feature of
this iatrogenic syndrome [1—3, 12, 131. Although the bone
biopsy remains the definitive "gold standard" for the diagnosis
of ABD, it is invasive, expensive and not readily available [4].
Thus, efforts have been made to develop non-invasive test
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Fig. 3. The false negative rates (FNR) for aluminum bone disease (ABD) were sign jficantly higher in patients who had discontinued their
aluminum gels for 6 months prior to their DFO test (0) than those who remained on their aluminum gels () . This difference was significant
(all P < 0.005) whether delta [Al]  3700 flM (or 100 pg/liter) (A) or  5550 nM (or 150 pg/liter) (B) was used (see text for details).
strategies for the serial monitoring and identification of those
patients at risk of developing ABD [2, 5—8].
Delta [Al], after infusion of a standard dose of DFO, has been
used to provide an indirect estimation of the tissue and bone
aluminum content [2—7, 10, 13, 17, 181, and certain cut-offs of
delta [Al] predictive of ABD have been defined in the HD
patients [2—6]. However, these diagnostic cut-offs were defined
in a group of highly selected patients. For example, delta [Al] 
7400 nM (or 200 sg/liter) in one large study yielded a PPV for
ABD of 81% with a SEN of 93% which appeared to be quite
reasonable. However, the prevalence (or pre-test probability)
of ABD in this study was 68% [5]. Thus, the actual gain of
diagnostic information was only marginal. Furthermore, the
predictive performances of delta [Al] test cut-offs have never
been examined in a large PD population.
Our present study was designed to examine prospectively the
predictive performance of certain non-invasive test strategies in
a largely unselected group of PD and HD patients. An important
finding was that the cumulative exposure to aluminum gels and
the prevalences of different bone diseases were different be-
tween our PD and HD patients, so that the test performances of
the delta [Al] cut-offs in the two groups were not the same. Our
HD patients had significantly more cumulative aluminum expo-
sure and a much higher prevalence of OF/Mx lesions than our
PD patients (Table 1, Fig. 1). Since patients with OF/Mx lesions
tended to have the highest delta [Al] levels among the non-ABD
groups (Fig. 2), and therefore could give rise to false-positive
DFO test results [2], it was not surprising that delta [Al] level
alone was not a good predictor of ABD in our HD patients
(Table 3). In contrast, with less cumulative exposure to alumi-
num gels and a lower prevalence of OF/Mx lesions in our PD
Table 4. Predicting aluminum bone disease (ABD) by combined test
strategies based on delta [Al] and 1-84 PTH cut-offs in both
peritoneal and hemodialysis patients
Test combination
1-84
Delta [Al] PTHb
flM pM LR(+) PPV SEN NPV SPEC
Peritoneal dialysis patients (N = 142)
Prevalence (pre-test probability) of ABD = 22%
1850 and <20 8.7 0.70 0.61 0.90 0.93
N = 27
3700 and <20 24 0.88 0.48 0.87 0.98
N = 17
5550 and <20 1.00 0.36 0.85 1.00
N= 11
Hemodialysis patients (N = 117)
Prevalence (pre-test probability) of ABD = 33%
1850 and <20 5.7 0.75 0.79 0.90 0.83N 40
3700 and <20 13.2 0.87 0.66 0.85 0.95
N = 29
5550 and <20 45 0.95 0.45 0.79 0.99
N = 18
Delta [Al] 3700 nM and PTH <20 nM, and delta [Al]  5550 nat and
PTH < 20 M are the two best test combinations for predicting ABD.
a 3700 flM = 100 pg/liter
b 20 M = 200 pg/mIN = Number of patients who have satisfied the specific test
combination
patients, delta [Al] cut-offs of 3700 nM (100 pg/liter) or
nM (150 pg/liter) both yielded a high PPV or ABD and a
significant gain in diagnostic information (Table 3).
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We further examined the pattern of ingestion of aluminum
gels in our patients in relation to the timing of their DFO testing.
We found that in both HD and PD patients, discontinuation of
aluminum gel a six months prior to testing was associated with
a very high frequency of false negative DFO test results (Fig. 3)
and suboptimal sensitivities of the above test cut-offs (Tables 3
and 4). This observation would suggest that the DFO test is only
useful in reflecting the aluminum burden related to recent
exogenous intake. Upon discontinuation of aluminum intake for
several months, a more "fixed" pool of aluminum in certain
target tissues may not be reflected by this test since the
stainable bone surface aluminum in the biopsies of our patients
with ABD were not different whether they had discontinued
their aluminum gels or not. The explanation of this observation
is currently unknown and requires further studies on the
kinetics of aluminum transfer between the plasma compartment
(as in albumin or transferrin-aluminum complexes or free form)
and other target tissues of accumulation in response to the DFO
infusion [2, 3].
Patients with the OF/Mx lesions were more prevalent in our
HD population and represented a major source of false positive
cases in the DFO test. As patients with OF/Mx lesions generally
have higher levels of PTH as compared to patients with ABD,
test combinations based on results of high delta [Al] and low
PTH levels have been used to differentiate these two groups of
patients [4—6]. Indeed, our study showed that with this strategy
the prediction of ABD in our HD patients could be improved to
almost the same level as our PD patients. The two best
combinations for both patient groups were: delta [Al] a 3700
nM (100 pg/liter) and PTFI <20 M (200 pg/mI), and delta [Al]
a 5550 nM (150 pg/liter) and PTH < 20 p (Table 4). Patients
who satisfy the former test combinations have a PPV for ABD
a 85% from a pre-test probability (or prevalence of ABD) of 22
to 33%, whereas patients who satisfy the latter have almost a
diagnostic certainty. Both delta [Al] cut-off a 3700 or 5550 nr,i
should remain useful in our PD patients when the prevalence of
ABD falls to as low as 10 to 15% (Fig. 4). Similarly, both delta
[Al] a 3700 nM and PTH < 20 p, and delta [Al] a 5550 n and
PTH <20 p perform well with a significant gain in diagnostic
information even with prevalence of ABD as low as 5 to 10%
(Fig. 5).
Thus, non-invasive identification of patients with ABD is
possible using delta [Al] a 3700 or 5550 nat in PD patients, or
using the test combination based on delta [Al] a 3700 nat and
PTH < 20 M in both PD and HD patients. Patients who fulfill
these test conditions have a post-test probability of ABD in the
range of about 60 to 85% from a pre-test probability of 10 to
30%, and they would be placed in a "moderate to high-risk"
category for ABD. Further confirmation with a bone biopsy
may be necessary in some of these patients depending on the
treatment threshold of the individual clinician. On the other
hand, delta [Alj a 5550 n and PTH < 20 pat would be
expected to be highly diagnostic even when the prevalence of
ABD falls to 5% in the PD patients and 10% in the HD patients.
Therapeutic intervention (that is, with DFO treatment) may be
initiated without the need of a bone biopsy.
Non-invasive test strategies as defined above are most useful
for the serial monitoring and diagnosis of ABD in patients who
1
A MAI]10 3700 nM B SLAIJOFO 5550 flM
100 100
80 80
60 60
40 40
20
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Pre-test P(ABD), % Pre-test P(ABD), %
Fig. 4. Hypothetical analyses on the effects of decreasing prevalences in alumiiiu'n bone diser'ie o2' te post-test probabilities based on two delta
[Al] cut-offs. Symbols are: (-'0--) peritoneal dialysis; (—a—) hemodialysis. A. The predictive performance over a range of prevalences using delta [Al]
 3700 nat. B. The predictive performance in the same patients using delta [Al] a 5550 nat. These cut-offs remain useful in selecting "moderate
to high-risk" cases of ABD in our PD patients even with a prevalence of ABD as low as 10%. The actual prevalence of ABD in our patients was
denoted as .
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require continued treatment with aluminum gels for their phos-
phate control. These test conditions remain valid and useful
even when the prevalence of ABD falls to as low as 5 to 10%.
However, for patients who have discontinued their aluminum
gels for  six months, the utility of these strategies is limited
because of a very high frequency of false negative cases (or low
sensitivity). Thus, we would not recommend their use in this
setting. Iliac crest bone biopsy with proper aluminum staining
remains the diagnostic standard in these patients should they
develop clinical or laboratory findings suggestive of aluminum
intoxication [13, 171.
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Appendix A. Terms used to define a diagnostic test
Positive predictive value (PPV): Probability of having a disease in a
patient with a positive test result.
Negative predictive value (NPV): Probability of not having disease in
a patient with a negative test result.
Sensitivity (SEN): Probability of having a positive test result in a
person with a disease (that is, "true-positive rate").
Specificity (SPEC): Probability of not having a positive test result in
a patient without disease (that is, "true-negative rate").
Likelihood ratio: A measure of discrimination by a test result. The
odds that a given level of a diagnostic test result would be expected in
a patient with (as opposed to one without) the target disorder [that is,
SEN/(1 — SPEC)].
Appendix B. Application of Bayes' theorem in clinical
prediction
The post-test probability for a disease (D) after positive test result
(T) can be estimated by the Bayes' theorem [14, 153 using the following
formulae:
Pre-test probability of D
Pre-test odds for D =
(1 — Pre-test probability of D)
Post-test odds for D = Pre-test odds x likelihood ratio for T
Post-test odds for D
Post-test probability for D =
(1 ÷ Post-test odds for D)
where the pretest probability of D can be estimated using the
prevalence of D, and the likelihood ratio is a discrimination
characteristic of T defined as: sensitivity/(1 — specificity).
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